Position in ALXO
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$138,318
+$33,619 QoQ
Shares Held
68,987
-25.5% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#37
of 68 holders
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALXO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $99,952,720 across 160 Biotechnology names. ALXO ranks #130 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,831 | $2,959,983 | |
| 2 | ARDX |
Ardelyx, Inc.
|
473,061 | $2,833,635 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
178,301 | $2,285,818 | |
| 4 | NUVB |
Nuvation Bio Inc.
|
495,792 | $2,126,947 | |
| 5 | RXRX |
Recursion Pharmaceuticals, Inc.
|
669,568 | $2,055,573 | |
| 6 | WVE |
Wave Life Sciences Ltd.
|
282,719 | $2,049,712 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
90,960 | $1,979,289 | |
| 8 | IOVA |
Iovance Biotherapeutics, Inc.
|
557,085 | $1,955,368 |
All Filings in ALXO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $138,318 | 68,987 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $104,699 | 92,654 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $161,341 | 88,165 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $33,750 | 81,326 | Shares | Sole | 2025-07-22 | |
| 2024-09-30 | $87,731 | 48,204 | Shares | Sole | 2024-11-05 | |
| 2024-03-31 | $114,722 | 10,289 | Shares | Sole | 2024-05-03 | |
| 2023-06-30 | $95,602 | 12,730 | Shares | Sole | 2023-08-14 | |
| 2022-09-30 | $154,210 | 16,114 | Shares | Sole | 2022-11-14 | |
| 2021-12-31 | $520,122 | 24,203 | Shares | Sole | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||